Publications by authors named "A P Burlina"

Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal storage disorder with a broad clinical spectrum. Early diagnosis and initiation of treatment are crucial for improving outcomes, yet the disease often goes undiagnosed due to its rarity and phenotypic heterogeneity. This study aims to evaluate the feasibility and disease incidence of newborn screening (NBS) for ASMD in Italy.

View Article and Find Full Text PDF

Background: Long-chain fatty acid oxidation disorders (LC-FAOD) are rare and potentially life-threatening diseases that cause deficient energy production and accumulation of toxic metabolites. Despite dietary management, adherence to maximum fasting guidelines, restricted long-chain triglyceride intake and supplementation with medium-chain triglyceride (MCT) oil (current standard of care), most patients experience recurrent decompensation episodes that can require hospitalisation. Herein, we analysed the effectiveness and safety of triheptanoin (a highly purified, synthetic medium odd-chain triglyceride) treatment in a cohort of Italian patients with LC-FAOD.

View Article and Find Full Text PDF
Article Synopsis
  • Phenylketonuria is a genetic disorder due to a lack of the phenylalanine hydroxylase enzyme, leading to high levels of phenylalanine in the blood, which can result in neurological issues and cognitive dysfunction if not treated with a low-phenylalanine diet.
  • Pegvaliase is an FDA-approved treatment that helps lower phenylalanine levels in adults with the condition, even when they are not on a restricted diet.
  • A study on three adults treated with pegvaliase showed notable improvements in brain MRI results, indicating reduced white matter damage, and enhanced cognitive performance, specifically on tasks sensitive to brain function, marking a significant milestone in treatment outcomes for this disorder.
View Article and Find Full Text PDF

Managing Inherited Metabolic Disorders (IMDs) at risk for hypoglycemia, such as Glycogen Storage Diseases (GSDs), Hereditary Fructose Metabolism Disorders (HFMDs) and Congenital Hyperinsulinism (CH), poses challenges in dietary treatments and blood glucose monitoring. The effectiveness of Continuous Glucose Monitoring (CGM) remains a subject of ongoing debate, with IMD guidelines maintaining caution. Therefore, a systematic evaluation is needed to understand the potential benefits of CGM during dietary interventions.

View Article and Find Full Text PDF

Lysosomal storage disorders (LSDs) are a group of inherited metabolic diseases caused by dysfunction of the lysosomal system, with subsequent progressive accumulation of macromolecules, activation of inflammatory response, and cell death. Neurologic damage is almost always present, and it is usually degenerative. White matter (WM) involvement may be primary or secondary.

View Article and Find Full Text PDF